Home
About
FAQ
History (12)
Prognostic factors for successful conversion from cyclosporine to FK 506-based immunosuppressive therapy for refractory rejection after liver transplantation. US Multicenter FK 506 Liver Study Group.
Cholestenones
Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer.
BIGH3 protein and macrophages in retinal endothelial cell apoptosis.
Co-Investigator
See All 12 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Co-Investigator
Overview
contributes to
Wake Forest NeuroNext Clinical Site (WAKENN)